Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study

被引：0

作者：

Rugo, Hope S.

O'Shaughnessy, Joyce

Cortes, Javier

Bardia, Aditya

Hamilton, Erika P.

Hurvitz, Sara A.

Kaklamani, Virginia G.

Romero, Paula Munoz

Vallespir, Bartomeu Piza

Wasserman, Tomer

Theall, Kathy Puyana

Tolaney, Sara M.

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA

[3] Quironsalud Grp, Int Breast Canc Ctr IBCC, Barcelona, Spain

[4] UCLA Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Univ Washington, Sch Med, Seattle, WA USA

[7] Fred Hutchinson Canc Ctr, Seattle, WA USA

[8] Univ Texas Hlth Sci Ctr, San Antonio, TX USA

[9] Menarini Grp, Florence, Italy

[10] Menarini Grp, New York, NY USA

[11] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1069

引用

页数：1